 | PharmaPoint: HIV Germany Drug Forecast and Market Analysis to 2022Viral Infections◇ 医療 介護 福祉 RCP |
1ListofFiguresFigure1SymptomsHIV17Table3MostPrescribedDrugsforHIV,201282Table30ComparisonofTherapeuticClassesinDevelopmentforHIVTherapeuticsMarket?DriversandBarriers,201282Table30ComparisonofTherapeuticClasses,201249Table15ProductProfile?Cobicistat85Table32CobicistatSWOTAnalysis,201283Table31ProductProfile?572-Trii104Table38572-Trii101Table38572-Trii102Table37ProductProfile?Dolutegravir97Table36DolutegravirSWOTAnalysis,201270Table28ClinicalUnmetNeeds?CurrentLevelofAttainment72Table28ClinicalUnmetNeeds?CurrentLevelofAttainment70Table28ClinicalUnmetNeeds?GapAnalysis,201283Table30ComparisonofTherapeuticClassesinDevelopmentforHIV,201219Table3SalesforHIV18Table3SalesforHIV18Table3SalesForecasts($b)forTruvada,2012?2022117"本商品は、直接お問い合わせください。
| PharmaPoint: HIV Germany Drug Forecast and Market Analysis to 2022Viral Infections◇ 医療 介護 福祉 RCP |
次>